117,442 Shares in Kyverna Therapeutics, Inc. $KYTX Purchased by Wellington Management Group LLP

Wellington Management Group LLP bought a new position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 117,442 shares of the company’s stock, valued at approximately $1,046,000. Wellington Management Group LLP owned 0.19% of Kyverna Therapeutics as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Public Employees Retirement System of Ohio bought a new stake in shares of Kyverna Therapeutics during the third quarter valued at about $28,000. Legal & General Group Plc bought a new position in shares of Kyverna Therapeutics in the second quarter valued at approximately $36,000. Qube Research & Technologies Ltd purchased a new position in Kyverna Therapeutics during the second quarter valued at approximately $43,000. Rhumbline Advisers grew its stake in Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after acquiring an additional 5,694 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new position in Kyverna Therapeutics during the third quarter valued at approximately $77,000. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Down 1.2%

Shares of NASDAQ KYTX opened at $7.26 on Friday. Kyverna Therapeutics, Inc. has a 12 month low of $3.78 and a 12 month high of $13.67. The company has a current ratio of 9.06, a quick ratio of 9.06 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $448.98 million, a price-to-earnings ratio of -2.47 and a beta of 1.98. The business has a 50-day moving average of $8.09 and a 200-day moving average of $8.49.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Wednesday, August 12th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.05. Sell-side analysts expect that Kyverna Therapeutics, Inc. will post -2.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on KYTX shares. Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Kyverna Therapeutics in a research report on Wednesday, June 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Wednesday, June 24th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.